Galectin-3 Inhibition in MASH Cirrhosis: Synthesizing Evidence from the NAVIGATE Trial and Emerging Therapeutics
Highlights
- The Phase 2b NAVIGATE trial demonstrated that belapectin (2 mg/kg) reduced the incidence of new esophageal varices by 50% in the per-protocol population of patients with MASH cirrhosis.
- Galectin-3 inhibition represents a novel therapeutic mechanism targeting the fibrotic and inflammatory cascades driving portal hypertension.
- Machine learning-derived histological scores (SNOF) have emerged as powerful tools for predicting hepatic venous pressure gradient (HVPG) and variceal development.
- Safety profiles for belapectin remain favorable across multiple trials, with no significant safety signals identified over 18 months of therapy.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.